Release Date: 2024-05-28

Relationship Between Dyslipidemia and Alzheimer’s Disease

Mine Kucur (Author), Ibrahim Murat Bolayirli (Author)

Release Date: 2024-05-28

Dyslipidemia may affect AD development through mechanisms involving ApoE4 levels, neuroinflammation, oxidative stress, cholesterol interactions with amyloid plaques and synaptic function, and vascular components. Increased cholesterol levels alter the blood-brain barrier’s permeability, potentially contributing to AD. ApoE, particularly its ε4 allele, is a significant genetic risk factor for AD. ApoE is involved in lipid transport [...]

Media Type

  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inAlzheimer’s Disease From Molecular Mechanisms to Clinical Practices
First Page275
Last Page297
DOIhttps://doi.org/10.69860/nobel.9786053359166.12
ISBN978-605-335-916-6 (PDF)
LanguageENG
Page Count23
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

Dyslipidemia may affect AD development through mechanisms involving ApoE4 levels, neuroinflammation, oxidative stress, cholesterol interactions with amyloid plaques and synaptic function, and vascular components. Increased cholesterol levels alter the blood-brain barrier’s permeability, potentially contributing to AD. ApoE, particularly its ε4 allele, is a significant genetic risk factor for AD. ApoE is involved in lipid transport and neural repair, with isoforms affecting AD pathology differently. ApoE4 is less effective in lipidation and promotes Aβ aggregation, reducing clearance and increasing deposition. This leads to neuroinflammation, tau hyperphosphorylation, and synaptic dysfunction. Cholesterol’s role in AD is linked to its influence on membrane properties, synaptic function, and Aβ production. High cholesterol levels can exacerbate Aβ generation and disrupt synaptic processes. Targeting these processes, along with managing dyslipidemia, offers potential pathways for mitigating AD progression.

Mine Kucur (Author)
Professor, Istanbul Cerrahpasa University
https://orcid.org/0000-0002-6579-1996
3Mine Kucur was born on April 29, 1971, in Istanbul. She graduated from Istanbul University Cerrahpaşa Medical Faculty in 1995. She completed a residency program in the Medical Biochemistry Department of the Cerrahpaşa Medical Faculty in 2001. In 2009, she was promoted to the position of associate professor of medical biochemistry and, in 2015, to the rank of professor. She currently serves as a professor at the Medical Biochemistry Department of Cerrahpasa Medical Faculty and is also the director of the medical biochemistry laboratory at Cerrahpaşa Medical Faculty, Prof. Dr. Murat Dilmener Hospital. She is the associated editor of the Journal of Academic Research in Medicine. Her primary clinical research interests include inflammation, pediatrics, immunology, and clinical laboratory processes.

Ibrahim Murat Bolayirli (Author)
Professor, Istanbul Cerrahpasa University
https://orcid.org/0000-0001-5755-7860
3I. Murat Bolayırlı was born on February 19, 1970, in Istanbul. He graduated from Istanbul University Cerrahpaşa Medical Faculty in 1994. He completed a residency program in the Medical Biochemistry Department of the Cerrahpaşa Medical Faculty in 1999. In 2009, he was promoted to the position of associate professor of medical biochemistry and, in 2015, to the rank of professor. He is currently Head of the Medical Biochemistry Department of Cerrahpasa Medical Faculty and serves as a professor at the Fikret Biyal Biochemistry Laboratory of Cerrahpasa Medical Faculty. He served as a member of the board of the Turkish Biochemistry Society between 2012-2015. He is the associated editor of the Turkish Journal of Biochemistry. His primary clinical research interests include endocrinology, nephrology, geriatrics, and clinical laboratory processes.

  • Remaley A, Dayspring TD, Warnick GR. Lipids, lipoproteins, apolipoproteins and other cardiovascular risk factors.. In. Burtis CA, Bruns DE, (eds), Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics. 7th ed. St. Louis.Saunders-Elsevier 2015;539-604.

  • Ferrier DR. Cholesterol, lipoprotein and steroid metabolism. In. Ferrier DR. (eds), Lippincott Illustrated Reviews.7th ed. Wolter Kluver 2017; 219-245.

  • Basavaraju P, Balasubramani R, Kathiresan DS, Devaraj I, Babu K, Alagarsamy V, et al. Genetic Regulatory Networks of Apolipoproteins and Associated Medical Risks.Front Cardiovasc Med. 2022; 8:788852.

  • Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr Rev.2022; 13:43(4):611-653.

  • Dybiec J, Baran W, Dąbek B, Fularski P, Młynarska E, Radzioch E, et al. Advances in Treatment of Dyslipidemia. Int J Mol Sci. 2023; 24(17):13288.

  • Fox CS, Pencina MJ, Wilson PW, Paynter NP, Vasan RS, D’Agostino RB Sr. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008; 31:1582–1584.

  • Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. Jama. 1979; 241:2035–2038.

  • Warraich HJ, Rana JS. Dyslipidemia in diabetes mellitus and cardiovascular disease. Cardiovasc Endocrinol. 2017; 6(1):27-32.

  • Tonkin A, Byrnes A. Treatment of dyslipidemia. F1000Prime Rep. 2014; 6:17.

  • Du Z, Qin Y. Dyslipidemia and Cardiovascular Disease: Current Knowledge, Existing Challenges, and New Opportunities for Management Strategies. J Clin Med. 2023; 12(1):363.

  • Liu T, Zhao D, Qi Y. Global Trends in the Epidemiology and Management of Dyslipidemia. J Clin Med. 2022; 11(21):6377.

  • Mutalifu M, Zhao Q, Wang Y, Hamulati X, Wang YS, Deng L, et.al. Joint association of physical activity and diet quality with dyslipidemia: a cross-sectional study in Western China. Lipids in Health and Disease. 2024; 23(1):46.

  • Gu D, Wang D, Zhu Q, Luo L, Zhang T. Prevalence of dyslipidemia and associated factors in sedentary occupational population from Shanghai: a cross-sectional study. Archives of Public Health. 2024; 82(1):21.

  • Cho SMJ, Lee HJ, Shim JS, Song BM, Kim HC. Associations between age and dyslipidemia are differed by education level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort. Lipids Health Dis. 2020; 19(1):12.

  • Gupta R, Sharma M, Goyal NK, Bansal P, Lodha S, Sharma KK. Gender differences in 7 years trends in cholesterol lipoproteins and lipids in India: Insights from a hospital database. Indian J Endocrinol Metab. 2016; 20(2): 211–218.

  • Rus M, Crisan S, Andronie-Cioara FL, Indries M, Marian P, Pobirci OL, et al. Prevalence and Risk Factors of Metabolic Syndrome: A Prospective Study on Cardiovascular Health. Medicina (Kaunas). 2023; 59(10):1711.

  • Ghodeshwar GK, Dube A, Khobragade D. Impact of Lifestyle Modifications on Cardiovascular Health: A Narrative Review. Cureus. 2023; 15(7):e42616.

  • Tsao CW, Aday AW, Almarzooq ZI, Anderson C A.M, Arora P, Avery C L et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation. 2023; 147(8): e93-e621.

  • Borghi C, Fogacci F, Agnoletti D, Cicero AFG. Hypertension and Dyslipidemia Combined Therapeutic Approaches. High Blood Press Cardiovasc Prev. 2022; 29(3): 221–230.

  • Wazir M, Olanrewaju OA, Yahya M, Kumari J, Kumar N, Singh J, et al. Lipid Disorders and Cardiovascular Risk: A Comprehensive Analysis of Current Perspectives. Cureus. 2023; 15(12):e51395.

  • Kris-Etherton PM, Petersen KS, Després JP. Anderson CAM, Deedwania P, Furie K et al. Strategies for Promotion of a Healthy Lifestyle in Clinical Settings: Pillars of IdealCardiovascular Health: A Science Advisory From the American Heart Association. Circulation. 2021; 144 (24):e495–e514.

  • Chen X, Zhou L, Hussain M. Lipids and lipoproteins. In: McPherson RA, Pincus MR (eds); Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. Elsevier 2017; 221-243.

  • Rader D, Hobbs H. Disorders of lipoprotein metabolism. In Kasper DL, Braunwald E, Fauci A et al eds. Harrison's Principles of Internal Medicine. 2004; 16th ed. McGraw-Hill Professional; 2286-229.

  • Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N et al. Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021; 37(8):1129-1150,

  • Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. Group ESCSD. 2019. ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1):111-188.

  • Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. AHA/ACC/AACVPR/AAPA /ABC /ACPM /ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A report of the American College of Cardiology/American Heart Association Task Force of Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082–e1143.

  • Mannu GS, Zaman MJ, Gupta A, Rehman HU, Myint PK. Evidence of lifestyle modification in the management of hypercholesterolemia. Curr Cardiol Rev. 2013; 9(1):2-14.

  • Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a casecontrol study. Lancet.2005; 366(9497): 1640-1649.

  • Nordoy A, Goodnight Sh. Dietary lipids and thrombosis. Relationships to atherosclerosis. Arteriosclerosis. 1990; 10(2): 149-163.

  • Dalal JJ, Khan T.Managing dyslipidaemia in young adults. Indian Heart J. 2024; 76 Suppl 1:S101-103.

  • Liang M, Pan Y, Zhong T, Zeng Y, Cheng ASK. Effects of aerobic, resistance, and combined exercise on metabolic syndrome parameters and cardiovascular risk factors: a systematic review and network meta-analysis. Rev Cardiovasc Med. 2021; 22(4):1523–1533.

  • Durstine Jl, Grandjean Pw, Cox Ca, Thompson PD. Lipids, lipoproteins, and exercise. J Cardiopulm Rehabil. 2002; 22(6): 385-398.

  • Whelton Sp, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002; 136(7): 493-503.

  • Kelley Ga, Kelley Ks, Tran Zv. Walking and resting blood pressure in adults: a meta-analysis. Prev Med. 2001; 33: 120-127.

  • Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. Sports Med. 2004; 34(6): 371-418.

  • Mora S, Yanek Lr, Moy Tf, Fallin Md, Becker Lc, Becker Dm. Interaction of body mass index and framingham risk score in predicting incident coronary disease in families. Circulation. 2005; 111(15): 1871-1876.

  • Halle M, Berg A, Garwers U, Grathwohl D, Knisel W, Keul J. Concurrent reductions of serum leptin and lipids during weight loss in obese men with type II diabetes. Am J Physiol. 1999; 277:E277-282.

  • Hawkins RI. Smoking, platelets and thrombosis. Nature. 1972; 236(5348): 450-452.

  • Meade TW, Imeson J, Stirling Y. Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet. 1987; 2(8566): 986-988.

  • Lakier JB. Smoking and cardiovascular disease. Am J Med. 1992; 93(1A): 8S-12S.

  • Kottke TE, Battista RN, DeFriese GH, Brekke ML. Attributes of successful smoking cessation interventions in medical practice. A meta-analysis of 39 controlled trials. JAMA. 1988; 259(19):2883-2889.

  • Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer Disease. In: StatPearls [Internet]. Treasure Island (FL): 2022; StatPearls Publishing.

  • Sato N, Morishita R. Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: short- and long-term modification by non-genetic risk factors. Front Aging Neurosci. 2013; 5:64.

  • Clark LR, Berman SE, Rivera-Rivera LA, Hoscheidt SM, Darst BF, Engelman CD, et al. Macrovascular and microvascular cerebral blood flow in adults at risk for Alzheimer's disease. Alzheimers Dement (Amst). 2017; 7:48-55.

  • Akyol O, Akyol S, Chou MC, Chen S, Liu CK, Selek S, et al. Lipids and lipoproteins may play a role in the neuropathology of Alzheimer's disease. Front Neurosci. 2023; 17:1275932.

  • Reitz C. Dyslipidemia and the risk of Alzheimer's disease. Curr Atheroscler Rep. 2013; 15(3):307..

  • Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD. Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology. 2001; 57: 1447–1452.

  • Wanamaker BL, Swige KJ, Blumenthal RS, Martin SS. Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol.2015; 38: 243–250.

  • Ezkurdia A, Ramírez MJ, Solas M.Metabolic Syndrome as a Risk Factor for Alzheimer's Disease: A Focus on Insulin Resistance.Int J Mol Sci. 2023; 24(5):4354.

  • Santos CY, Snyder PJ, Wu WC, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis.Alzheimers Dement (Amst).2017; 7:69-87.

  • Mansoori N, Tripathi M, Luthra K, Alam R, Lakshmy R, Sharma S, et al. MTHFR (677 and 1298) and IL-6-174 G/C genes in pathogenesis of Alzheimer’s and vascular dementia and their epistatic interaction. Neurobiol Aging. 2012; 33:1003 e1–8.

  • Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G.Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013; 9(2):106-18.

  • Husain MA, Laurent B, Plourde M.APOE and Alzheimer's Disease: From Lipid Transport to Physiopathology and Therapeutics. Front Neurosci. 2021; 15:630502.

  • Kockx M, Jessup W, Kritharides L. Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 2008; 28(6):1060–1067.

  • Kang SS, Ebbert MT, Baker K, Cook C, Wang X, Sens JP, et al. Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, and tau. J. Exp. Med. 2018; 215: 2235–2245.

  • Getz GS, Reardon CA.Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J Lipid Res. 2009; 50:S156-61.

  • Huang Y, Mahley RW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis. 2014; 72 A:3-12.

  • Yu JT, Tan L, Hardy J. Apolipoprotein E in Alzheimer’s disease: anupdate. Annu. Rev. Neurosci. 2014; 37:79–100.

  • Singh RK, Haka AS, Asmal A, Barbosa-Lorenzi VC, Grosheva I, Chin HF, et al. TLR4 (toll-like receptor 4)-dependent signaling drives extracellular catabolism of LDL (low-density lipoprotein) aggregates. Arterioscler Thromb Vasc Biol. 2020; 40: 86–102.

  • Mahley RW, Rall SC. Apolipoprotein E.Far more than a lipid transport protein, Annu Rev Genomics Hum Genet. 2000; 1: 507–537.

  • Corbo RM, Scacchi R. Apolipoprotein E (APOE) allele distribution in the world. Is APOE* 4 a ‘thrifty’allele? Ann Hum Genet. 1999; 63: 301–310.

  • Egert S, Rimbach G, Huebbe P. ApoE genotype: from geographic distribution to function and responsiveness to dietary factors. Proc Nutr Soc. 2012; 71: 410–424.

  • Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997; 278: 1349–1356.

  • Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families, Science. 1993; 261:921-923.

  • Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer’s disease. Annu Rev Med. 1996; 47:387-400.

  • Sohrabi HR, Bates KA, Rodrigues M, Taddei K, Martins G, Laws SM, et al. The Relationship between memory complaints, perceived quality of life and mental health in apolipoprotein Eε4 carriers and non-carriers. J Alz Dis. 2009;17:69-79.

  • Rueter J, Rimbach G, Huebbe P. Functional diversity of apolipoprotein E: from subcellular localization to mitochondrial function. Cell Mol Life Sci. 2022; 79(9):499.

  • Hu J, Liu CC, Chen XF, Zhang YW, Xu H, Bu G. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice. Mol Neurodegener. 2015; 10:6.

  • Flowers SA, Rebeck GW. APOE in the normal brain. Neurobiol Dis. 2020; 136:104724.

  • Kaneyiko T, Xu H, Bu G. ApoE and Aβ in Alzheimer’s disease: accidental encounters or partners? Neuron. 2014; 81(4):740–754.

  • Nguyen D, Dhanasekaran P, Nickel M, Nakatani R, Saito H, Phillips MC, et al. Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4. Biochemistry. 2010; 49(51):10881–10889.

  • Hubin E, Verghese P. B, van Nuland N, Broersen K. Apolipoprotein E associated with reconstituted high-density lipoprotein-like particles is protected from aggregation. FEBS Lett. 2019; 593: 1144–1153.

  • Kim J, Basak JM, Holtzman DM. The role of Apolipoprotein E in Alzheimer‘s disease. Neuron. 2009; 63:287-304.

  • Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, et al. ApoE promotes the proteolytic degradation of Aβ. Neuron. 2008; 58:681-693.

  • Schipper HM. Apolipoprotein E: Implicationsfor AD neurobiology, epidemiology and risk assessment. Neurobiol Aging. 2011; 32:778-790.

  • Lozupone M, Panza F. Impact of apolipoprotein E isoforms on sporadic Alzheimer's disease: beyond the role of amyloid beta. Neural Regen Res. 2024; 19(1):80-83.

  • Huang Y. Aβ-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer‘s disease. Trends Mol Med. 2010; 16:287-294.

  • Zhong N. Apolipoprotein E4 domain interaction induces endoplasmic reticulum stress and impairs astrocyte function. J Biol Chem. 2009; 284(40):27273-27280.

  • Zhong N, Weisgraber KH. Understanding the association of apolipoprotein E4 with Alzheimer‘s disease: clues from its structure. J Biol Chem. 2009; 284:6027-6031.

  • Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, et all. Disclosure of APOE genotype for risk of Alzheimer‘s Disease. N Engl J Med. 2009; 361:245-254.

  • Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, Rosenthal E, et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer‘s disease: patterns of linkage disequilibrium and disease/marker association. Genomics 2007; 89:655-66.

  • Salvadó G, Grothe MJ, Groot C, Moscoso A, Schöll M, Gispert JD. Alzheimer’s Disease Neuroimaging Initiative Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia. Eur J Nucl Med Mol Imaging. 2021; 48:2212-2224.

  • Zhou X, Shi Q, Zhang X, Gu L, Li J, Quan S, et al. ApoE4-mediated blood-brain barrier damage in Alzheimer's disease: Progress and prospects. Brain Res Bull. 2023; 199:110670.

  • Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience. 1995; 69(3):757–761.

  • Bennett DA, De Jager PL, Leurgans SE, Schneider JA. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology. 2009; 72(17):1495–1503.

  • Serrano-Pozo A, Qian J, Monsell SE, Betensky RA, Hyman BT. APOEepsilon2 is associated with milder clinical andpathological Alzheimer disease. Ann Neurol. 2015; 77(6):917–929.

  • Li Z, Shue F, Zhao N, Shinohara M, Bu G.APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener. 2020; 15(1):63.

  • Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996; 14(1):55–61.

  • Van der Kant R, Goldstein LSB, Ossenkoppele R. Amyloid-beta-independent regulators of tau pathology in Alzheimer disease. Nat Rev Neurosci. 2020; 21(1):21–35.

  • Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Neurosci. 2020; 23(10):1183–1193.

  • DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019; 14(1):32.

  • Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, et al. Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation. Mol Neurodegener. 2016; 8;11(1):74.

  • Grinberg LT, Thal DR. Vascular pathology in the aged human brain. Acta Neuropath. 2019; 119: 277-290.

  • Seripa D, Panza F, Franceschi M, D'Onofrio G, Solfrizzi V, Dallapiccola B et all. Non-apolipoprotein E and apolipoprotein E genetics of sporadic Alzheimer‘s disease. Ageing Res Rev. 2009; 8:214-236.

  • Kao YC, Ho PC, Tu YK, Jou IM, Tsai KJ. Lipids and Alzheimer's Disease. Int J Mol Sci. 2020; 21(4):1505.

  • Huynh TV, Davis AA, Ulrich JD, Holtzman DM. Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. J Lipid Res. 2017; 58(5):824-836.

  • Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW, Bu G. ApoE4 Accelerates Early Seeding of Amyloid Pathology. Neuron. 2017; 96(5):1024-1032.

  • Zhu L, Zhong M, Elder GA, Sano M, Holtzman DM, Gandy S, et al. Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer's disease pathogenesis. Proc Natl Acad Sci U S A. 2015; 112(38):11965-11970.

  • Cho HS, Hyman BT, Greenberg SM, Rebeck GW. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Aβ aggregation. J Neuropathol Exp Neurol. 2001; 60, 342–349.

  • Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW. et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011; 3(89):89ra57.

onix_3.0::thothThoth ONIX 3.0
onix_3.0::project_museProject MUSE ONIX 3.0
onix_3.0::oapenOAPEN ONIX 3.0
onix_3.0::jstorJSTOR ONIX 3.0
onix_3.0::google_booksGoogle Books ONIX 3.0
onix_3.0::overdriveOverDrive ONIX 3.0
onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
csv::thothThoth CSV
json::thothThoth JSON
kbart::oclcOCLC KBART
bibtex::thothThoth BibTeX
doideposit::crossrefCrossRef DOI deposit
onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
marc21record::thothThoth MARC 21 Record
marc21markup::thothThoth MARC 21 Markup
marc21xml::thothThoth MARC 21 XML

Share This Chapter!